Related Experiment Video

Updated: Aug 26, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.5K

Verbena Attenuates Adriamycin-Induced Renal Tubular Injury via Inhibition of ROS-ERK1/2-NLRP3 Signal Pathway

Yicen Zhou1, Qijing Wu2, Zhenfang Du1

  • 1Department of Nephropathy, Center Laboratory, Zhangjiagang Traditional Chinese Medicine Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang 215600, Jiangsu, China.

Evidence-Based Complementary and Alternative Medicine : Ecam
|October 10, 2022
PubMed

Insights

Verbena extract protects kidney cells from damage in chronic kidney disease (CKD) models. It works by inhibiting the ROS-ERK1/2-NLRP3 pathway, offering a new target for kidney disease treatment.

Area of Science:

  • Nephrology
  • Pharmacology
  • Traditional Chinese Medicine

Background:

  • Chronic kidney disease (CKD) is a significant global health issue.
  • Tubular epithelial cell injury is a key factor in CKD progression.
  • Protecting tubular cells is crucial for delaying CKD.

Purpose of the Study:

  • To investigate the renoprotective mechanism of verbena in kidney diseases.
  • To explore the potential of total aqueous extract of verbena (TAEV) in treating tubular injury.
  • To identify novel therapeutic targets for kidney diseases.

Main Methods:

  • Adriamycin (ADR)-induced renal tubular cell injury model in vitro.
  • Assessed cell disruption, viability, and apoptosis.
  • Investigated the role of ROS-ERK1/2-NLRP3 signaling pathway.

Main Results:

  • TAEV ameliorated ADR-induced tubular cell disruption and loss of viability.
  • TAEV significantly reduced ADR-induced apoptosis.
  • TAEV inhibited the ROS-ERK1/2-mediated activation of the NLRP3 signal pathway.

Conclusions:

  • TAEV demonstrates promising renoprotective effects against tubular injury.
  • The ROS-ERK1/2-NLRP3 pathway is a potential therapeutic target for kidney diseases.
  • Verbena may serve as a novel agent for delaying CKD progression.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

515
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
53
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
784
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
143
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
872